Hart, Charles E.,Lynch, Samuel E.,Young, Conan S.,Perrien, Dan
申请号：
AU2013203292
公开号：
AU2013203292A1
申请日:
2013.04.10
申请国别(地区):
AU
年份:
2013
代理人:
摘要：
#$%^&*AU2013203292A120130502.pdf#####H:\AMnI\Inenvoven\NRPortb\DCC\AMh5O59376_ .DOC-9/04/2013 THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS: 1. A method of preventing or inhibiting vertebral compression fractures comprising: providing a composition comprising a PDGF solution disposed in a biocompatible matrix and, applying the composition to at least one vertebral body. 2. The method of claim 1, wherein applying comprises injecting the at least one vertebral body with the composition. 3, The method of claim 1, wherein the at least one vertebral body comprises a high risk vertebrae body. 4. A method for promoting or accelerating bone formation in a vertebral body comprising: providing a composition comprising a PDGF solution disposed in a biocompatible matrix and, applying the composition to at least one vertebral body. 5. The method of claim 4, further comprising providing at least one pharmaceutical composition and, administering the pharmaceutical composition locally to a patient. 6. The method of claim 5, wherein administering the pharmaceutical composition locally comprises disposing the pharmaceutical composition in or around the at least one vertebral body. 7. The method of claim 4, further comprising providing at least one pharmaceutical composition and, administering the pharmaceutical composition systemically to a patient. 8. The method of claim 7, wherein administering the pharmaceutical composition systemically comprises oral administration, intravenous administration, or combinations thereof. 9. The method of claim 5, wherein the patient is an individual with osteoporosis. 10. The method of claim 5, wherein the patient is an individual that has undergone kyphoplasty or vertebroplasty. 42WO 2008/151193 PCT/US2008/065666 11. A composition for promoting bone formation in a vertebral body comprising: a solution comprising platelet derived growth factor (PDGF) a biocompatible matrix and, 5 at least one contrast agent, wherein the solution and the
